EYLEA

GPTKB entity

Statements (47)
Predicate Object
gptkbp:instanceOf gptkb:drug
gptkbp:administeredBy ophthalmologist
gptkbp:approvalYear 2011
gptkbp:approvedBy gptkb:FDA
gptkb:EMA
gptkbp:ATCCode S01LA05
gptkbp:brand gptkb:EYLEA
gptkbp:chemicalClass gptkb:protein
gptkbp:contraindication active intraocular inflammation
ocular infection
hypersensitivity to aflibercept
gptkbp:developedBy gptkb:Bayer
gptkb:Regeneron_Pharmaceuticals
gptkbp:drugClass anti-VEGF agent
gptkbp:form intravitreal injection
solution for injection
gptkbp:genericName gptkb:aflibercept
gptkbp:halfLife ~7 days (in vitreous)
https://www.w3.org/2000/01/rdf-schema#label EYLEA
gptkbp:indication gptkb:diabetic_macular_edema
gptkb:neovascular_age-related_macular_degeneration
diabetic retinopathy
macular edema following retinal vein occlusion
gptkbp:legalStatus prescription only
gptkbp:macromoleculeType gptkb:VEGF-A
gptkb:VEGF-B
gptkb:placental_growth_factor_(PlGF)
gptkbp:marketedAs gptkb:Bayer
gptkb:Regeneron_Pharmaceuticals
gptkbp:mechanismOfAction VEGF inhibitor
gptkbp:notRecommendedFor pediatric patients
gptkbp:patentExpired 2023 (US)
gptkbp:pregnancyCategory C (US)
gptkbp:prescribes adults
gptkbp:product recombinant fusion protein
gptkbp:routeOfAdministration intravitreal injection
gptkbp:sideEffect glaucoma
conjunctival hemorrhage
eye pain
increased intraocular pressure
vitreous detachment
endophthalmitis
retinal detachment
gptkbp:storage 2°C to 8°C
gptkbp:website https://www.eylea.us/
gptkbp:bfsParent gptkb:Regeneron
gptkbp:bfsLayer 6